|
1
|
Stupp R, Mason WP, van der Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
De Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hegi ME, Liu L, Herman JG, Stupp R, Wick
W, Weller M, Mehta MP and Gilbert MR: Correlation of
O6-methylguanine methyltransferase (MGMT) promoter methylation with
clinical outcomes in glioblastoma and clinical strategies to
modulate MGMT activity. J Clin Oncol. 26:4189–4199. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schuster J, Lai RK, Recht LD, Reardon DA,
Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan
A, et al: A phase II, multicenter trial of rindopepimut (CDX-110)
in newly diagnosed glioblastoma: The ACT III study. Neuro Oncol.
17:854–861. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Narita Y: Bevacizumab for glioblastoma.
Ther Clin Risk Manag. 11:1759–1765. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reardon DA, Herndon JE II, Peters KB,
Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES,
Sathornsumetee S, et al: Bevacizumab continuation beyond initial
bevacizumab progression among recurrent glioblastoma patients. Br J
Cancer. 107:1481–1487. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abrams DA, Hanson JA, Brown JM, Hsu FP,
Delashaw JB Jr and Bota DA: Timing of surgery and bevacizumab
therapy in neurosurgical patients with recurrent high grade glioma.
J Clin Neurosc. 22:35–39. 2015. View Article : Google Scholar
|
|
9
|
Swanson KD, Lok E and Wong ET: An overview
of alternating electric fields therapy (NovoTTF Therapy) for the
treatment of malignant Glioma. Curr Neurol Neurosci Rep. 16:82016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stupp R, Taillibert S, Kanner AA, Kesari
S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink
KL, et al: Maintenance therapy with tumor-treating fields plus
temozolomide vs temozolomide alone for glioblastoma: A randomized
clinical trial. JAMA. 314:2535–2543. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen TC, Da Fonseca CO and Schönthal AH:
Preclinical development and clinical use of perillyl alcohol for
chemoprevention and cancer therapy. Am J Cancer Res. 5:1580–1593.
2015.PubMed/NCBI
|
|
12
|
da Fonseca CO, Schwartsmann G, Fischer J,
Nagel J, Futuro D, Quirico-Santos T and Gattass CR: Preliminary
results from a phase I/II study of perillyl alcohol intranasal
administration in adults with recurrent malignant gliomas. Surg
Neurol. 70:259–267. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
da Fonseca CO, Simão M, Lins IR, Caetano
RO, Futuro D and Quirico-Santos T: Efficacy of monoterpene perillyl
alcohol upon survival rate of patients with recurrent glioblastoma.
J Cancer Res Clin Oncol. 137:287–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Da Fonseca CO, Teixeira RM, Silva JC, DE
Saldanha DA, Fischer J Gama, Meirelles OC, Landeiro JA and
Quirico-Santos T: Long-term outcome in patients with recurrent
malignant glioma treated with Perillyl alcohol inhalation.
Anticancer Res. 33:5625–5631. 2013.PubMed/NCBI
|
|
15
|
Cross H: Epilepsy: Behavioural,
psychological, and ketogenic diet treatments. BMJ Clin Evid.
2015:pii: 12142015.
|
|
16
|
Rho JM: How does the ketogenic diet induce
anti-seizure effects? Neurosci Lett. 637:4–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bruna J, Miró J and Velasco R: Epilepsy in
glioblastoma patients: Basic mechanisms and current problems in
treatment. Expert Rev Clin Pharmacol. 6:333–344. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kargiotis O, Markoula S and Kyritsis AP:
Epilepsy in the cancer patient. Cancer Chemother Pharmacol.
67:489–501. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Armstrong TS, Grant R, Gilbert MR, Lee JW
and Norden AD: Epilepsy in glioma patients: Mechanisms, management,
and impact of anticonvulsant therapy. Neuro Oncol. 18:779–789.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liberti MV and Locasale JW: The warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kroemer G and Pouyssegur J: Tumor cell
metabolism: Cancer's Achilles' heel. Cancer Cell. 13:472–482. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu J, Tan M and Cai Q: The Warbu'rg effect
in tumor progression: Mitochondrial oxidative metabolism as an
anti-metastasis mechanism. Cancer Lett. 356:156–164. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Seyfried TN, Flores R, Poff AM, D'Agostino
DP and Mukherjee P: Metabolic therapy: A new paradigm for managing
malignant brain cancer. Cancer Lett. 356:289–300. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bhattacharya B, Omar MF Mohd and Soong R:
The Warburg effect and drug resistance. Br J Pharmacol.
173:970–979. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Woolf EC, Syed N and Scheck AC: Tumor
metabolism, the ketogenic diet and -hydroxybutyrate: Novel
approaches to adjuvant brain tumor therapy. Front Mol Neurosci.
9:1222016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Klement RJ, Champ CE, Otto C and Kämmerer
U: Anti-tumor effects of ketogenic diets in mice: A meta-analyais.
PLoS One. 11:e01550502016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Abdelwahab MG, Fenton KE, Preul MC, Rho
JM, Lynch A, Stafford P and Scheck AC: The ketogenic diet is an
effective adjuvant to radiation therapy for the treatment of
malignant glioma. PLoS One. 7:e361972012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Maroon JC, Seyfried TN, Donohue JP and
Bost J: The role of metabolic therapy in treating glioblastoma
multiforme. Surg Neurol Int. 6:612015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zuccoli G, Marcello N, Pisanello A,
Servadei F, Vaccaro S, Mukherjee P and Seyfried TN: Metabolic
management of glioblastoma multiforme using standard therapy
together with a restricted ketogenic diet: Case report. Nutr Metab
(Lond). 7:332010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Champ CE, Palmer JD, Volek JS,
Werner-Wasik M, Andrews DW, Evans JJ, Glass J, Kim L and Shi W:
Targeting metabolism with a ketogenic diet during the treatment of
glioblastoma multiforme. J Neurooncol. 117:125–131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schwartz K, Chang HT, Nikolai M, Pernicone
J, Rhee S, Olson K, Kurniali PC, Hord NG and Noel M: Treatment of
glioma patients with ketogenic diets: Report of two cases treated
with an IRB-approved energy-restricted ketogenic diet protocol and
review of the literature. Cancer Metab. 3:32015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wagner M and Moore DD: Endoplasmic
reticulum stress and glucose metabolism. Curr Opin Clin Nutr Metab
Care. 14:367–373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schönthal AH, Chen TC, Hofman FM, Louie SG
and Petasis NA: Preclinical development of novel anti-glioma drugs
targeting the endoplasmatic reticulum stress response. Curr Pharm
Des. 17:2428–2438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kato H and Nishitoh H: Stress responses
from the endoplasmic reticulum in cancer. Front Oncol. 5:932015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peñaranda Fajardo NM, Meijer C and Kruyt
FA: The endoplasmatic reticulum stress/unfolded protein responde in
gliomagenesis, tumor progression and as a therapeutic target in
glioblastoma. Biochem Pharmacol. 118:1–8. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Johnson GG, White MC and Grimaldi M:
Stressed to death: Targeting endoplasmic reticulum stress response
induced apoptosis in gliomas. Curr Pharm Des. 17:284–292. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cho HY, Wang W, Jhaveri N, Torres S, Tseng
J, Leong MN, Lee DJ, Goldkorn A, Xu T, Petasis NA, et al: Perillyl
alcohol for the treatment of temozolomide-resistant gliomas. Mol
Cancer Ther. 11:2462–2472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schonthal AH: Targeting endoplasmic
reticulum stress for cancer therapy. Front Biosci (Schol Ed).
4:412–431. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Strowd RE III and Grossman SA: The role of
glucose modulation and dietary supplementation in patients with
central nervous system tumors. Curr Treat Options Oncol. 16:362015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kambach DM, Halim AS, Cauer AG, Sun Q,
Tristan CA, Celiku O, Kesarwala AH, Shankavaram U, Batchelor E and
Stommel JM: Disabled cell density sensing leads to dysregulated
cholesterol synthesis in glioblastoma. Oncotarget. 8:14860–14875.
2017.PubMed/NCBI
|
|
41
|
Murai T, Maruyama Y, Mio K, Nishiyama H,
Suga M and Sato C: Low cholesterol triggers membrane
microdomain-dependent CD44 shedding and suppresses tumor cell
migration. J Biol Chem. 286:1999–2007. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Da Fonseca CO, Silva JT, Lins IR, Simão M,
Arnobio A, Futuro D and Quirico-Santos T: Correlation of tumor
topography and peritumoral edema of recurrent malignant gliomas
with therapeutic response to intranasal administration of perillyl
alcohol. Invest New Drugs. 27:557–564. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Woolf EC, Curley KL, Liu Q, Turner GH,
Charlton JA, Preul MC and Scheck AC: The ketogenic diet alters the
hypoxic response and affects expression of proteins associated with
angiogenesis, invasive potential and vascular permeability in a
mouse glioma model. PLoS One. 10:e01303572015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nygren C, von Holst H, Månsson JE and
Fredman P: Increased levels of cholesterol esters in glioma tissue
and surrounding areas of human brain. Br J Neurosurg. 11:216–220.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang X, Qin J, Zhao Y, Shi J, Lan R, Gan
Y, Ren H, Zhu B, Qian M and Du B: Long-term ketogenic diet
contributes to glycemic control but promotes lipid accumulation and
hepatic steatosis in type 2 diabetic mice. Nutr Res. 36:349–358.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zamani GR, Mohammadi M, Ashrafi MR, Karimi
P, Mahmoudi M, Badv RS, Tavassoli AR and Malamiri R Azizi: The
effects of classic ketogenic diet on serum lipid profile in
children with refractory seizures. Acta Neurol Belg. 116:529–534.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sharma S, Gulati S, Kalra V, Agarwala A
and Kabra M: Seizure control and biochemical profile on the
ketogenic diet in young children with refractory epilepsy-Indian
experience. Seizure. 18:446–449. 2009. View Article : Google Scholar : PubMed/NCBI
|
